Latest filing published 13 Dec 2022 for HTG Molecular Diagnostics, INC, €402.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Byron Lawson: trading record in brief
This profile gathers the share dealings of Byron Lawson in HTG Molecular Diagnostics, Inc, where the filings describe the role as senior executive. In total, 16 filings cover trades dated from 31 March 2020 to 9 December 2022.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The record was last updated on 13 December 2022 with a share grant (€402) in HTG Molecular Diagnostics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Byron Lawson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,000 shares@ US$0.4254.2% of flowCommon StockSEC:0001209191-22-061009:0
- 23 shares@ US$1.030.2% of flowCommon StockSEC:0001209191-22-040341:0
- 1,000 shares@ US$0.4764.9% of flowCommon StockSEC:0001209191-22-036956:0
- 23 shares@ US$1.390.6% of flowCommon StockSEC:0001209191-22-022392:0
- 24 shares@ US$5.422.2% of flowCommon StockSEC:0001209191-22-000857:0
- 896 shares@ US$3.561554.1% of flowCommon StockSEC:0001209191-21-069780:0
- 24 shares@ US$5.712.3% of flowCommon StockSEC:0001209191-21-058992:0
- 24 shares@ US$5.812.3% of flowCommon StockSEC:0001209191-21-045190:0
- 354 shares@ US$3.918521.8% of flowCommon StockSEC:0001209191-21-040446:0
9 of 9 declarations